ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023
Garden City, NY, May 11, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next generation biotech, genomics and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2023.
- Financial highlights for the three months ended March 31, 2023, include the following:
Net revenue of $19.3 million for the three months ended March 31, 2023, as compared to $47.5 million for the three months ended March 31, 2022. - Adjusted EBITDA of $3.1 million for the three months ended March 31, 2023, as compared to adjusted EBITDA of $14.6 million for the three months ended March 31, 2022.
- For the three months ended March 31, 2023, net revenue was $19.3 million as compared to $47.5 million for the three months ended March 31, 2022.
- Diagnostic services costs for the three months ended March 31, 2023 were $1.2 million compared to $4.7 million for the three months ended March 31, 2022.